Benign clinical course following atomoxetine overdose [1]

Clinical Toxicology

Volumn 43, Issue 1, 2005, Pages 57-

  Cantrell, F Lee ^a,b   Nestor, Mike ^c  

^a California Poison Control System   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ATOMOXETINE;

ANOREXIA; ATTENTION DEFICIT DISORDER; CASE REPORT; DIZZINESS; DRUG ERUPTION; DRUG OVERDOSE; DRUG SAFETY; FATIGUE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; LETTER; MALE; PHYSICAL EXAMINATION; SCHOOL CHILD; CLINICAL FEATURE; EMERGENCY WARD;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DIAGNOSIS, DIFFERENTIAL; EMERGENCY TREATMENT; HUMANS; MALE; OVERDOSE; PROPYLAMINES;

EID: 13144287469     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-45053     Document Type: Letter

References (4)

1. Product Information: Strattera(TM), Atomoxetine. Eli Lilly & Co.: Indianapolis, IN, 2002.
2. Witcher JW, Long A, Smith B, Sauer JM, Heilgenstein J, Wilens T, Spencer T, Biederman J. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol Spring 2003; 13(1):53-63.
3. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther Dec 2003; 25(12):3065-3083.
4. Eiland LS, Guest AL. Atomoxetine treatment of attention-deficit/ hyperactivity disorder. Ann Pharmacother Jan 2004; 38(1):86-90.